Navigation Links
Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director
Date:11/23/2009

SEATTLE, Nov. 23 /PRNewswire/ -- Immune Design Corp. (IDC) announced today that Dr. Bruce L.A. Carter has joined IDC as Executive Chairman. Dr. Carter has a successful track record in biotechnology executive management. He was the former Chief Executive Officer at ZymoGenetics, in Seattle, WA and Chief Scientific Officer at Novo Nordisk, Copenhagen, Denmark.

(Photo: http://www.newscom.com/cgi-bin/prnh/20091123/SF15228)

Dr. Steven Reed, IDC's founder and Chief Executive Officer commented, "I am delighted to welcome Dr. Bruce Carter as a new member of IDC's management team and Board of Directors. His appointment and his broad biotech experience signifies our commitment to building a strong company that delivers on its scientific objectives. He is a great addition to IDC."

"With Dr. Steven Reed's expertise on vaccine adjuvants and Dr. David Baltimore's and Dr. Thomas Dubensky's expertise on the lentivirus-based vectors to introduce antigens to dendritic cells, IDC is poised to develop new improved vaccines to a world that desperately needs them," said Dr. Carter.

Dr. Carter possesses a unique combination of strong leadership skills and technical expertise in progressing healthcare products from the bench to the clinic, and ultimately to the people who need them.

Dr. Carter currently serves on the Board of ZymoGenetics, Dr. Reddy's Laboratories, the Hyderabad, India based generic drug maker, QLT, Inc. Vancouver, Canada and the nonprofit Global Alliance TB Drug Development Board, New York, NY. He joins IDC after a long career in the biotechnology and pharmaceutical arena.

Dr. Carter began his career in drug discovery at G. D. Searle. In 1986, he was appointed as V.P. and Head of Research & Development at ZymoGenetics. In 1994 he became a Corporate Executive V.P. at Novo Nordisk, as well as Chief Scientific Officer. In 2000, Dr. Carter led the negotiations that established ZymoGenetics as an independent company from Novo Nordisk and he became the CEO transforming the company from the research arm of a European company to a company that developed and commercialized Recothrom®.

IDC - Innovative Science

IDC's goal is to develop and commercialize new safe and effective vaccine products to prevent or target infectious and malignant diseases. IDC utilizes proprietary Toll-like receptor-4 agonist adjuvant and lentivirus-based vector platforms, which both target dendritic cells and are used to deliver antigens together with desired immunostimulatory signals.

For more information, go to www.immunedesign.com.


Contact:

Cassie Ostrander 206-826-7901 or
cassie.ostrander@immunedesign.com

SOURCE Immune Design Corp.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response
2. RNL BIO Rescues a College Student from Autoimmune Hearing Loss
3. MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology
4. Peptimmune to Collaborate on Dengue Virus Vaccine and Point-Of-Care Diagnostic With Two DOD Biomedical Research Facilities
5. Octapharma Aims to Expand U.S. Immune Globulin Therapy Portfolio
6. Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors
7. MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014
8. Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009
9. Fast Forward, LLC and Amplimmune, Inc. Join Forces to Speed New Treatments to People with MS**
10. AutoImmune Inc. Reports 2009 Second Quarter Financial Results
11. Transposagen Creates a Rat Model of the Human Immune System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... Rosalind™, the first-ever genomics analysis platform specifically designed for life science researchers ... honor of pioneering researcher Rosalind Franklin, who made a major contribution to ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 system ... experiments and avoiding the use of exogenous expression plasmids. The simplicity of programming ... systematic gain-of-function studies. , This complement to loss-of-function studies, such as with ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ComplianceOnline’s Medical Device ... on 7th and 8th June 2018 in San Francisco, CA. The Summit brings together ... as several distinguished CEOs, board directors and government officials from around the world to ...
(Date:10/11/2017)... , Oct. 11, 2017  VMS BioMarketing, a leading ... a nationwide oncology Clinical Nurse Educator (CNE) network, which will ... need for communication among health care professionals to enhance the ... nurses, office staff, and other health care professionals to help ... breast cancer. ...
Breaking Biology Technology:
(Date:5/16/2017)...  Veratad Technologies, LLC ( www.veratad.com ), an innovative ... verification solutions, announced today they will participate as a ... thru May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions ... evolving digital world, defining identity is critical to nearly ...
(Date:4/24/2017)... , April 24, 2017 ... and partner with  Identity Strategy Partners, LLP (IdSP) ... "With or without President Trump,s March 6, 2017 ... Terrorist Entry , refugee vetting can be instilled with ... resettlement. (Right now, all refugee applications are suspended ...
(Date:4/17/2017)... Florida , April 17, 2017 NXT-ID, ... technology company, announces the filing of its 2016 Annual Report on ... and Exchange Commission. ... on Form 10-K is available in the Investor Relations section of ... as on the SEC,s website at http://www.sec.gov . ...
Breaking Biology News(10 mins):